122 related articles for article (PubMed ID: 29894293)
1. Oncogenic BRAFV600E drives expression of MGL ligands in the colorectal cancer cell line HT29 through N-acetylgalactosamine-transferase 3.
Sahasrabudhe NM; Lenos K; van der Horst JC; Rodríguez E; van Vliet SJ
Biol Chem; 2018 Jun; 399(7):649-659. PubMed ID: 29894293
[TBL] [Abstract][Full Text] [Related]
2. MGL ligand expression is correlated to BRAF mutation and associated with poor survival of stage III colon cancer patients.
Lenos K; Goos JA; Vuist IM; den Uil SH; Delis-van Diemen PM; Belt EJ; Stockmann HB; Bril H; de Wit M; Carvalho B; Giblett S; Pritchard CA; Meijer GA; van Kooyk Y; Fijneman RJ; van Vliet SJ
Oncotarget; 2015 Sep; 6(28):26278-90. PubMed ID: 26172302
[TBL] [Abstract][Full Text] [Related]
3. Characterization of Macrophage Galactose-type Lectin (MGL) ligands in colorectal cancer cell lines.
Pirro M; Rombouts Y; Stella A; Neyrolles O; Burlet-Schiltz O; van Vliet SJ; de Ru AH; Mohammed Y; Wuhrer M; van Veelen PA; Hensbergen PJ
Biochim Biophys Acta Gen Subj; 2020 Apr; 1864(4):129513. PubMed ID: 31911241
[TBL] [Abstract][Full Text] [Related]
4.
Pirro M; Mohammed Y; van Vliet SJ; Rombouts Y; Sciacca A; de Ru AH; Janssen GMC; Tjokrodirijo RTN; Wuhrer M; van Veelen PA; Hensbergen PJ
Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32752259
[TBL] [Abstract][Full Text] [Related]
5. COSMC knockdown mediated aberrant O-glycosylation promotes oncogenic properties in pancreatic cancer.
Hofmann BT; Schlüter L; Lange P; Mercanoglu B; Ewald F; Fölster A; Picksak AS; Harder S; El Gammal AT; Grupp K; Güngör C; Drenckhan A; Schlüter H; Wagener C; Izbicki JR; Jücker M; Bockhorn M; Wolters-Eisfeld G
Mol Cancer; 2015 May; 14():109. PubMed ID: 26021314
[TBL] [Abstract][Full Text] [Related]
6. Glycoproteomic Analysis of MGL-Binding Proteins on Acute T-Cell Leukemia Cells.
Pirro M; Schoof E; van Vliet SJ; Rombouts Y; Stella A; de Ru A; Mohammed Y; Wuhrer M; van Veelen PA; Hensbergen PJ
J Proteome Res; 2019 Mar; 18(3):1125-1132. PubMed ID: 30582698
[TBL] [Abstract][Full Text] [Related]
7. Tn antigen interactions of macrophage galactose-type lectin (MGL) in immune function and disease.
Tumoglu B; Keelaghan A; Avci FY
Glycobiology; 2023 Dec; 33(11):879-887. PubMed ID: 37847609
[TBL] [Abstract][Full Text] [Related]
8. Identification of a secondary binding site in human macrophage galactose-type lectin by microarray studies: Implications for the molecular recognition of its ligands.
Marcelo F; Supekar N; Corzana F; van der Horst JC; Vuist IM; Live D; Boons GPH; Smith DF; van Vliet SJ
J Biol Chem; 2019 Jan; 294(4):1300-1311. PubMed ID: 30504228
[TBL] [Abstract][Full Text] [Related]
9. Activation of the C-Type Lectin MGL by Terminal GalNAc Ligands Reduces the Glycolytic Activity of Human Dendritic Cells.
Zaal A; Li RJE; Lübbers J; Bruijns SCM; Kalay H; van Kooyk Y; van Vliet SJ
Front Immunol; 2020; 11():305. PubMed ID: 32161592
[TBL] [Abstract][Full Text] [Related]
10. Crystal Structure of the Carbohydrate Recognition Domain of the Human Macrophage Galactose C-Type Lectin Bound to GalNAc and the Tumor-Associated Tn Antigen.
Gabba A; Bogucka A; Luz JG; Diniz A; Coelho H; Corzana F; Cañada FJ; Marcelo F; Murphy PV; Birrane G
Biochemistry; 2021 May; 60(17):1327-1336. PubMed ID: 33724805
[TBL] [Abstract][Full Text] [Related]
11. BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells.
Goulielmaki M; Koustas E; Moysidou E; Vlassi M; Sasazuki T; Shirasawa S; Zografos G; Oikonomou E; Pintzas A
Oncotarget; 2016 Feb; 7(8):9188-221. PubMed ID: 26802026
[TBL] [Abstract][Full Text] [Related]
12. Targeting Tn-Antigen-Positive Human Tumors with a Recombinant Human Macrophage Galactose C-Type Lectin.
Bulteau F; Thépaut M; Henry M; Hurbin A; Vanwonterghem L; Vivès C; Le Roy A; Ebel C; Renaudet O; Fieschi F; Coll JL
Mol Pharm; 2022 Jan; 19(1):235-245. PubMed ID: 34927439
[TBL] [Abstract][Full Text] [Related]
13. Human T cell activation results in extracellular signal-regulated kinase (ERK)-calcineurin-dependent exposure of Tn antigen on the cell surface and binding of the macrophage galactose-type lectin (MGL).
van Vliet SJ; Vuist IM; Lenos K; Tefsen B; Kalay H; García-Vallejo JJ; van Kooyk Y
J Biol Chem; 2013 Sep; 288(38):27519-27532. PubMed ID: 23918927
[TBL] [Abstract][Full Text] [Related]
14. Tumor-associated Tn-MUC1 glycoform is internalized through the macrophage galactose-type C-type lectin and delivered to the HLA class I and II compartments in dendritic cells.
Napoletano C; Rughetti A; Agervig Tarp MP; Coleman J; Bennett EP; Picco G; Sale P; Denda-Nagai K; Irimura T; Mandel U; Clausen H; Frati L; Taylor-Papadimitriou J; Burchell J; Nuti M
Cancer Res; 2007 Sep; 67(17):8358-67. PubMed ID: 17804752
[TBL] [Abstract][Full Text] [Related]
15. The Plasticity of the Carbohydrate Recognition Domain Dictates the Exquisite Mechanism of Binding of Human Macrophage Galactose-Type Lectin.
Diniz A; Coelho H; Dias JS; van Vliet SJ; Jiménez-Barbero J; Corzana F; Cabrita EJ; Marcelo F
Chemistry; 2019 Nov; 25(61):13945-13955. PubMed ID: 31404475
[TBL] [Abstract][Full Text] [Related]
16. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer.
Smeby J; Sveen A; Merok MA; Danielsen SA; Eilertsen IA; Guren MG; Dienstmann R; Nesbakken A; Lothe RA
Ann Oncol; 2018 May; 29(5):1227-1234. PubMed ID: 29518181
[TBL] [Abstract][Full Text] [Related]
17. N-glycosylated proteins and distinct lipooligosaccharide glycoforms of Campylobacter jejuni target the human C-type lectin receptor MGL.
van Sorge NM; Bleumink NM; van Vliet SJ; Saeland E; van der Pol WL; van Kooyk Y; van Putten JP
Cell Microbiol; 2009 Dec; 11(12):1768-81. PubMed ID: 19681908
[TBL] [Abstract][Full Text] [Related]
18. The Tn antigen promotes lung tumor growth by fostering immunosuppression and angiogenesis via interaction with Macrophage Galactose-type lectin 2 (MGL2).
da Costa V; van Vliet SJ; Carasi P; Frigerio S; García PA; Croci DO; Festari MF; Costa M; Landeira M; Rodríguez-Zraquia SA; Cagnoni AJ; Cutine AM; Rabinovich GA; Osinaga E; Mariño KV; Freire T
Cancer Lett; 2021 Oct; 518():72-81. PubMed ID: 34144098
[TBL] [Abstract][Full Text] [Related]
19. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.
Dawson H; Galván JA; Helbling M; Muller DE; Karamitopoulou E; Koelzer VH; Economou M; Hammer C; Lugli A; Zlobec I
Int J Cancer; 2014 May; 134(10):2342-51. PubMed ID: 24166180
[TBL] [Abstract][Full Text] [Related]
20. Ligand Recognition by the Macrophage Galactose-Type C-Type Lectin: Self or Non-Self?-A Way to Trick the Host's Immune System.
Szczykutowicz J
Int J Mol Sci; 2023 Dec; 24(23):. PubMed ID: 38069400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
